top of page

ASGCT 2026: Benitec Biopharma presented a clinical update of its lead DNA-directed RNA interference program targeting Oculopharyngeal Muscular Dystrophy (OPMD)

  • May 15
  • 1 min read

Executive Chair & CEO Jerel Banks describes how Benitec is programing the body to create its own internal continuous RNAi factory to treat this disease. With this clinical data in hand, Benitec plans to meet with FDA about the design of a pivotal trial.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page